<DOC>
	<DOCNO>NCT02242149</DOCNO>
	<brief_summary>This study conduct test hypothesis uncontrolled type 2 diabetic adult treatment diacerein improve glycemic control reduce liver fat within 24 month period .</brief_summary>
	<brief_title>Efficacy Study Diacerein Glycemic Control Liver Fat Type 2 Diabetes Subjects</brief_title>
	<detailed_description>Background : Recently , knowledge diacerhein , anthraquinone drug powerful anti-inflammatory property , reveal drug improves insulin sensitivity , mediate reversal chronic subclinical inflammation . Amongst numerous pathogenetic factor , oxidative stress apoptosis hepatocytes initiate many inflammatory process involve progression Non alcoholic fatty liver disease . Aims : The aim evaluate effect treatment diacerein improvement glycemic parameter ( mean glycated hemoglobin , fast blood sugar ) reduction liver fat fraction . Methods : Two-hundred patient randomly allocate either treatment diacerein plus usual therapeutic regimen placebo 24 month . Clinic , laboratory evaluation ( include glycated hemoglobin , fast blood sugar , creatinine , ferritin , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , g-glutamyl transpeptidase , alkaline phosphatase , bilirubin , albumin , prothrombin time , platelet count , total cholesterol , high-density low-density lipoprotein cholesterol triglycerides urinary albumin excretion rate 24-hour urine collection ) perform every 3 month end study . Pro-Inflammatory cytokine , adiponectin cytokeratin-18 measure , 12 month end study . Liver fat fraction measurement use control attenuation parameter ( CAP ) transient elastography . ( Fibroscan ) perform 12 24-month treatment , observer blind allocation group .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Diacetylrhein</mesh_term>
	<criteria>Type 2 diabetes . Presence liver steatosis diagnose ultrasound transient elastography ( Fibroscan® ) Age 3075 year . HbA1c 7.5 9.5 least 8 week prior screen . Stable diabetes therapeutic regimen consist either diet , oral hypoglycemic agent without insulin 8 week prior randomization . Body mass index &gt; 40 kg/m2 Serum creatinine ≥180mmol/L estimate glomerular filtration rate &lt; 30 ml/min . Presence serious concomitant disease , pulmonary disease malignant disorder . Current daily alcohol ingestion ≥20 g. Hepatotoxic drug . Presence chronic liver disease nonalcoholic fatty liver disease , include hepatitis B virus hepatitis C virus infection , hemochromatosis , Wilson 's disease , alfa1 antitrypsin deficiency , autoimmune hepatitis . Women seek pregnancy . Current use previous use within 6 month vitamin E pioglitazone</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Fat liver</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Diacerein</keyword>
	<keyword>Transient elastography</keyword>
	<keyword>Treatment</keyword>
</DOC>